OUR MISSION
Is to develop high value, differentiated cardiovascular therapeutics based on validated targets and modes of action
R&D programs Targeted diseasesNews
15.11.2010
Biocitech Park, Paris (France), November...
15.11.2010
Parc Biocitech, Paris (France), le 15 no...
13.07.2010
Biocitech Park, Paris (France), July ...
13.07.2010
Parc Biocitech, Paris (France), le 8 ...
Latest News
Endotis Pharma initiates phase IIa study of first-in-class neutralizable anticoagulant in open-heart surgeryBiocitech Park, Paris, France, June 22, 2011
Endotis Pharma, a world leader in the development of neutralizable anticoagulants, today announced enrolment of the first patients into a Phase IIa study using EP217609 and...
Latest Publications
Endotis Pharma presents Phase I clinical trial resultsfor a first-in-class synthetic parenteral neutralizable anticoagulant EP217609at the 21st International Congress on ThrombosisBiocitech Park, Paris (France), July 8th, 2010 - Endotis Pharma, the biopharmaceutical company dedicated to the discovery and development of small-glyco drugs for applications i...